References
- Yarden Y., Kuang W. J., Yang-Feng T., Coussens L., Manemitsu L., Dull T. J., Chen E., Schlessinger J., Franke U., Ullrich A. Human proto-oncogene c-kit: A new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO Journal 1987; 6: 3341–3351
- Zsebo K. M., Wypych J., McNiece I. K., Lu H. S., Smith K. A., Karkare S. B., Sachdev R. K., Yuscenkoff V. N., Birkett N. C., Williams L. R., Satyagal V. N., Tung W., Bosselman R. A., Endiaz E. A., Langley K. E. Identification, purification, and biological characterization of hematopoietic stem cell factor from Buffalo rat liver-conditioned medium. Cell 1990; 63: 195–201
- Gunji Y., Nakamura M., Osawa H., Nagayoshi K., Nakauchi H., Miura Y., Yanagisawa M., Suda T. Human primitive hematopoietic progenitor cells are more enriched in KITlow cells that KIThigh cells. Blood 1993; 82: 3283–3289
- Turner A. M., Lin N., Bennet L. G., Broudy V. C. A biologically active soluble form of the c-kit receptor is produced by the OCIM1 human leukemia cell line by post-translational processing. Blood 1993; 82: 230a
- Wypych J., Bennett L. G., Schwatz M. G., Clogston C. L., Lu H. S., Broudy V. C., Bartley T. D., Parker V. P., Langley K. E. Soluble kit receptor in human serum. Blood 1995; 85: 66–73
- Limanni A., Baker W. H., Chang C. M., Seemann R., Williams D. E., Patchen M. L. c-kit ligand gene expression in normal and sublethally irradiated mice. Blood 1995; 85: 2377–2384
- Cairo M. S., Gillan E. R., Weinthal J., Van de Ven C., Ho W., Shen V., Buzby J. S., Suen Y. Decreased endogenous circulating Steel factor (STF) levels following allogeneic and autologous BMT: lack of an inverse correlation with post-BMT myeloid engraftment. Bone Marrow Transplantation 1993; 11: 155–161
- Hashino S., Imamura M., Kobayashi S., Tanaka J., Kasai M., Sakurada K., Asaka M. Soluble c-kit levels in acute GVHD after allogeneic bone marrow transplantation. Br. J. Haematol. 1995; 89: 897–899
- Imamura M., Hashino S., Kobayashi H., Tanaka J., Imai K., Fujii Y., Kobayashi M., Han M., Kasai M., Sakurada K., Miyazaki T. In vivo administration of interleukin-6 in murine allogeneic bone marrow chimeras: early and delayed enhancement of hematopoiesis accompanied with split tolerance but not with graft-versus-host disease. Jmmunobiology 1994; 190: 346–367
- Gale R. P., Bortin M. M., Van Bekkum D. W., Biggs J. C., Dick K. A., Gluckman E., Good R. A., Hoffmann R. G., Kay H. E. M., Kersey J. H., Marmont A., Masaoka T., Rimm A. A., Van Rood J. J., Zwaan F. E. Risk factors for acute graft-versus-host disease. Br. J. Haematol. 1987; 67: 397–406
- Nash R. A., Pepe M. S., Storb R., Longton G., Pettinger M., Anasetti C., Appelbaum F. R., Bowden R. A., Deeg H. J., Doney K., Martin P. J., Sullivan K. M., Sanders J., Witherspoon R. P. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood, 80: 1838–1845
- Antin J. H., Ferrara J. L.M. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964–2968
- Turner A. M., Zsebo K. M., Martin F., Jacobsen F. W., Bennet L. G., Broudy V. C. Non hematopoietic tumor cell lines express stem cell factor and display c-kit receptors. Blood 1992; 80: 374–381